Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655604 | 0.79 | HDAC3 (0.37) | HTTNPSR1MEN1LMNAMAPT | |
| SCHEMBL14117366 | 0.77 | SMN1; SMN2 (0.49) | HTTLMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL1003874 | 0.76 | POLB (0.47) | HTTNPSR1LMNAMAPTKMT2A | |
| SCHEMBL1005549 | 0.72 | ALDH1A1 (0.47) | LMNASMN1; SMN2KDM4E | |
| SCHEMBL25779498 | 0.71 | MEN1 (0.43) | NPSR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL13655599 | 0.70 | NPC1 (0.55) | HTTNPSR1LMNAMAPTKMT2A | |
| SCHEMBL25644373 | 0.69 | P2RX7 (0.42) | LMNA | |
| SCHEMBL24574912 | 0.68 | TAS1R3 (0.44) | HTTNPSR1MEN1LMNAMAPT | |
| SCHEMBL13655562 | 0.68 | HDAC3 (0.46) | KDM4E | |
| SCHEMBL9272367 | 0.66 | LMNA (0.41) | MEN1LMNAKMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090252678-A1 | COX-2-TARGETED IMAGING AGENTS | VANDERBILT UNIVERSITY (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252678-A1 | COX-2-TARGETED IMAGING AGENTS | PTGS2, PTGES2, PTGER2 | HTT 3805/4885NPSR1 351/4885MEN1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.